|
Getting your Trinity Audio player ready...
|
As the global race to treat metabolic dysfunction–associated steatotic liver disease (MASLD) and expand GLP-1 therapies accelerates, a critical challenge is emerging across the pharmaceutical industry: clinical trial infrastructure is struggling to scale—especially liver imaging.
With trial sizes increasing, durations extending, and global participation expanding, ENDRA Life Sciences (NASDAQ: NDRA) is positioning its TAEUS® (Thermo-Acoustic Enhanced UltraSound) technology as a potential solution to one of the largest inefficiencies in modern clinical trials.
Alongside ENDRA Life Sciences (NASDAQ: NDRA), other names drawing attention include Allogene Therapeutics (NASDAQ: ALLO), Nokia Corporation (NASDAQ: NOK), ImageneBio Inc (NASDAQ: IMA), and Sky Quarry Inc (NASDAQ: SKYQ), currently trading actively in early trading.
GLP-1 and MASLD Market Growth Is Outpacing Diagnostic Infrastructure
The GLP-1 receptor agonist market, a key driver of metabolic disease treatment, is projected to grow from approximately $66.4 billion in 2025 to over $185 billion by 2033. At the same time:
- Up to 30 million Americans are expected to be on GLP-1 therapies by 2030
- MASLD and MASH clinical programs are expanding globally
- Trials increasingly require longitudinal liver fat monitoring over 48–72 weeks
These dynamics are creating unprecedented demand for scalable liver imaging solutions.
MRI-Based Imaging Creates a Structural Bottleneck
Currently, MRI-PDFF remains the gold standard for liver fat measurement in clinical trials. However, it introduces significant constraints:
- Cost per scan: $1,500–$3,000
- Limited availability across global trial sites
- Dependence on hospital-based infrastructure
- Scheduling and throughput limitations
As trials scale into thousands of patients across hundreds of sites, imaging becomes a major cost driver and execution bottleneck.
TAEUS®: A Potential Reset of Clinical Trial Economics
ENDRA’s TAEUS® platform is designed to address these limitations by leveraging:
- Ultrasound-based infrastructure
- Point-of-care deployment
- Rapid, repeatable liver fat measurement
Internal modeling suggests that replacing MRI-based workflows with TAEUS could reduce imaging costs by approximately 90% to 96% per trial.
This represents more than incremental savings—it signals a potential structural reset in how clinical trial imaging is performed and funded.
Multi-Billion Dollar Efficiency Opportunity
At scale, the impact becomes significant.
ENDRA estimates that widespread adoption of TAEUS across GLP-1 and MASLD clinical trials could result in:
- Approximately $3.1 billion in imaging-related savings by 2025
- Expanding to roughly $7.0 billion by 2029
These projections reflect growing trial sizes, repeated imaging requirements, and broader global deployment.
The Bottom Line
The expansion of MASLD and GLP-1 therapies is creating parallel demand for scalable diagnostic infrastructure.
As clinical trials grow in size and complexity, imaging constraints are becoming increasingly visible.
ENDRA Life Sciences (NASDAQ: NDRA) is developing TAEUS to address this gap—offering a potential pathway to:
- Reduce imaging costs by over 90%
- Unlock billions in system-wide efficiencies
- Enable the next phase of global metabolic disease treatment
In a healthcare market defined by scale, infrastructure—not just innovation—may determine who wins.